Thirty-day mortality rates after immunotherapy initiation

SÜTCÜOĞLU O., Ilhan A., Tacar S. Y., GÜVEN D. C., Ucar G., Karadurmus N., ...More

IMMUNOTHERAPY, vol.13, pp.1419-1426, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 13
  • Publication Date: 2021
  • Doi Number: 10.2217/imt-2021-0082
  • Journal Name: IMMUNOTHERAPY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, EMBASE, MEDLINE
  • Page Numbers: pp.1419-1426
  • Keywords: antiaggregant drugs, atezolizumab, cancer, fatal side effects, hyperprogression, immune side effect, immunotherapy, nivolumab, palliative oncology, thromboembolism, CHECKPOINT INHIBITORS, CANCER-PATIENTS, LUNG-CANCER, REAL-WORLD, IPILIMUMAB, PEMBROLIZUMAB, CHEMOTHERAPY, NIVOLUMAB, TRIAL
  • Hacettepe University Affiliated: Yes


Background: The aim of this study was to determine the cause of death in patients who died within 30 days after the first dose of immunotherapy. Methods: The data of 1432 patients treated with immunotherapy in six tertiary referral hospitals were retrospectively analyzed. Results: It was determined that 34 (2%) of the patients died within 30 days after the first dose of immunotherapy. Death occurred in all patients who received palliative therapy, and most patients (88%) received immunotherapy as second- or subsequent-line of therapy. The most common cause of death was disease progression and thromboembolic events. Conclusion: Preliminary results of the current study might give some clues to define the patient population in whom the fatal side effects of immunotherapy might be encountered.